Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Baijin Life Science HoldingsMNNGF 26 Cyclically Adjusted PS Ratio is 1.25 as of Jul. 18, 2026, which is 84% above its 10-year median of 0.68. GuruFocus rates MNNGF with a GF Score™ of 26/100 and a GF Value™ of $0.05. The stock has 5 warning signs investors should review. Among 794 Retail - Cyclical companies, Baijin Life Science Holdings ranks worse than 81.11% on this metric.
The historical rank and industry rank for Baijin Life Science Holdings's Cyclically Adjusted PS Ratio or its related term are showing as below:
MNNGF'
s Cyclically Adjusted PS Ratio Range Over the Past 10 Years
Min: 0.33 Med: 0.68 Max: 1.78
Current: 1.62
During the past 13 years, Baijin Life Science Holdings's highest Cyclically Adjusted PS Ratio was 1.78. The lowest was 0.33. And the median was 0.68.
MNNGF's Cyclically Adjusted PS Ratio is ranked worse than 81.11% of 794
companies
in the Retail - Cyclical industry
Industry Median: 0.495
vs MNNGF: 1.62
The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.
Baijin Life Science Holdings's adjusted revenue per share data of for the fiscal year that ended in Mar25 was $0.025. Add all the adjusted revenue per share for the past 10 years together and divide 10 will get our Cyclically Adjusted Revenue per Share, which is $0.06 for the trailing ten years ended in Mar25.
Shiller PE for Stocks: The True Measure of Stock Valuation
Baijin Life Science Holdings (OTCPK:MNNGF) Cyclically Adjusted PS Ratio Explanation
Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.
If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.
Baijin Life Science Holdings Cyclically Adjusted PS Ratio Related Terms
Baijin Life Science Holdings Cyclically Adjusted PS Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Baijin Life Science Holdings Cyclically Adjusted PS Ratio Chart
MNNGF vs TPR: Cyclically Adjusted PS Ratio Comparison
For the Luxury Goods subindustry, Baijin Life Science Holdings's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Baijin Life Science Holdings Cyclically Adjusted PS Ratio vs Retail - Cyclical Industry
For the Retail - Cyclical industry and Consumer Cyclical sector, Baijin Life Science Holdings's Cyclically Adjusted PS Ratio distribution charts can be found below:
* The bar in red indicates where Baijin Life Science Holdings's Cyclically Adjusted PS Ratio falls into.
Baijin Life Science Holdings Cyclically Adjusted PS Ratio Calculation
Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.
The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.
What does a Cyclically Adjusted PS Ratio of 1.25 mean?
Baijin Life Science Holdings (MNNGF) has a Cyclically Adjusted PS Ratio of 1.25 as of Jul. 18, 2026. Cyclically Adjusted PS Ratio is the ratio of share price to a company's inflation-adjusted revenue per share over a 10-year period. View historical data on Baijin Life Science Holdings and its competitors. This is 84% above median its historical median of 0.68. Over the past decade, Baijin Life Science Holdings' Cyclically Adjusted PS Ratio has ranged from 0.33 to 1.78. According to the industry distribution chart, Baijin Life Science Holdings ranks #644 out of 794 companies in the Retail - Cyclical industry, placing it in the top 81.1%.
Is Baijin Life Science Holdings' Cyclically Adjusted PS Ratio too high?
Baijin Life Science Holdings' current Cyclically Adjusted PS Ratio of 1.25 is 84% above median its 10-year median of 0.68. Over the past 10 years, this metric has ranged from a low of 0.33 to a high of 1.78. The Retail - Cyclical industry median Cyclically Adjusted PS Ratio is 0.50. Baijin Life Science Holdings' value of 1.25 is 152.5% above this industry median. Based on the distribution chart, Baijin Life Science Holdings ranks #644 out of 794 companies in the Retail - Cyclical industry, which is in the bottom quartile relative to peers. Overall, Baijin Life Science Holdings has a GF Score™ of 26/100, reflecting its overall financial health beyond just this single metric.
How does Baijin Life Science Holdings' Cyclically Adjusted PS Ratio compare to TPR?
According to the Retail - Cyclical industry distribution chart, Baijin Life Science Holdings ranks #644 out of 794 companies for Cyclically Adjusted PS Ratio. This places Baijin Life Science Holdings in the lower half of its industry. The industry median Cyclically Adjusted PS Ratio is 0.50. Baijin Life Science Holdings' value of 1.25 is 152.5% above this benchmark. Historically, Baijin Life Science Holdings' own Cyclically Adjusted PS Ratio has ranged from 0.33 to 1.78 over the past decade. While the company's 10-year median is 0.68 vs. the industry median of 0.50, Baijin Life Science Holdings has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted PS Ratio for a Retail - Cyclical company?
The median Cyclically Adjusted PS Ratio among Retail - Cyclical companies is 0.50, based on 794 companies in the industry. Companies in the top quartile (top 25%) have a Cyclically Adjusted PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, Cyclically Adjusted PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Baijin Life Science Holdings's current Cyclically Adjusted PS Ratio of 1.25 is 152.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted PS Ratio mean?
A high Cyclically Adjusted PS Ratio can signal that a stock is expensive relative to its fundamentals. Cyclically Adjusted PS Ratio is the ratio of share price to a company's inflation-adjusted revenue per share over a 10-year period. View historical data on Baijin Life Science Holdings and its competitors. For the Retail - Cyclical industry, the median Cyclically Adjusted PS Ratio is 0.50 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Baijin Life Science Holdings's current Cyclically Adjusted PS Ratio is 1.25, which is 84% above median its own 10-year median of 0.68. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Baijin Life Science Holdings stock overvalued right now?
Baijin Life Science Holdings (MNNGF) has a current Cyclically Adjusted PS Ratio of 1.25. The stock's GF Value™ is $0.05, compared to a current price of $0.08 — trading 50% above its estimated fair value. The current Cyclically Adjusted PS Ratio is 1.25, which is 84% above median its 10-year median of 0.68 and 152.5% above the Retail - Cyclical industry median of 0.50. Baijin Life Science Holdings' overall GF Score™ is 26/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted PS Ratio calculated?
Cyclically Adjusted PS Ratio is calculated from a company's financial statements. For Baijin Life Science Holdings (MNNGF), the current Cyclically Adjusted PS Ratio is 1.25 as of Jul. 18, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Baijin Life Science Holdings (MNNGF) Overvalued in 2026?
Based on GuruFocus' analysis, Baijin Life Science Holdings stock appears to be overvalued.
The current stock price of $0.08 is trading 50% above its estimated GF Value™ of $0.05.
Key valuation signals for MNNGF:
Cyclically Adjusted PS Ratio: 1.25 (84% above median its 10-year median of 0.68)
GF Value™: $0.05 vs. price of $0.08 (50% above fair value)
Industry Position: 152.5% above the Retail - Cyclical median (#644 of 794)
No single metric tells the full story. See the MNNGF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Baijin Life Science Holdings Ltd is positioned as a biopharmaceutical company dedicated in anti-aging and preventive medicine, as well as cellular precision therapy. The company has three business segment: jewelry business segment; strategic investment segment; and skincare business segment. The majority of revenue is coming from jewelry business segment.
26GF Score
Get the complete analysis for MNNGF
Cyclically Adjusted PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MNNGF has been successfully added to your 
